Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema — BLUE SKY

Diabetic Macular Edema (DME) Clinical Trial

Official title:
OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Status Active, not recruiting

Clinical Trial Summary

This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care and will take place as per investigator's discretion. This includes e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice will be collected as part of the study.

Clinical Trial Description

BLUE SKY consists of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME". Patients will be enrolled at approximately 55 centers, which will be representatively distributed amongst the 16 German federal states. This will ensure to reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients will be included after decision to start treatment with brolucizumab and consent is given. All patients will be documented either in the AMD or DME-module (Full Analysis Set). For the BIRL module, only naïve nAMD patients enrolled in approximately 7 selected centers will be documented. All these centers are equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice will be collected as part of the study. The study eye will be defined as the first eye treated during the study, the other eye will be considered as fellow eye. If both eyes are treated at baseline, the eye with the worse VA will be chosen as the study eye (if VA is measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient will be up to 24 months. ;

Study Design

Related Conditions & MeSH terms

Diabetic Macular Edema (DME)
Edema
Macular Degeneration
Macular Edema
Neovascular Age-related Macular Degeneration (nAMD)
Vision Disorders
Vision, Low
Wet Macular Degeneration

Clinical Trial Details

NCT number	NCT04543331
Study type	Observational
Source	Novartis
Contact
Status	Active, not recruiting
Phase
Start date	November 5, 2020
Completion date	December 20, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01702441` - Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema	Phase 1/Phase 2
Completed	`NCT02424019` - Phase 4 IOP Signals Associated With ILUVIEN®	Phase 4
Completed	`NCT02633852` - Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema	Phase 4
Completed	`NCT04857996` - Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)	Phase 2
Recruiting	`NCT05919693` - A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)	Phase 1/Phase 2
Completed	`NCT04739306` - Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema	Phase 3
Recruiting	`NCT06116916` - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Phase 2
Completed	`NCT02050828` - The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema	Phase 2
Recruiting	`NCT03859245` - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention	N/A
Completed	`NCT02585401` - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada	N/A
Terminated	`NCT02080091` - Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies	N/A
Terminated	`NCT04697758` - Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema	Phase 1/Phase 2
Terminated	`NCT00936520` - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy	Phase 1
Not yet recruiting	`NCT05989126` - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.